Our Medicines

We are a global biopharmaceutical company focused on helping to address the unmet medical needs of patients with serious diseases. We are investing billions in Research and Development (R&D), which includes the discovery and development of new medicines.

Below is a list of our company's products. Any linked documents and websites are intended only for residents 18 years or older, as the availability of medicines and the indications for which they are approved can vary with country and region. 

Please refer to the Patient Leaflet information approved by the relevant governmental authority of the country where you are located and consult your physician for professional medical advice and services.

Pharmacovigilance Notice

This website has not been designed to collect safety information related to Bristol-Myers Squibb products.

Healthcare Professionals  

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Freepost, HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie

Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com

Patients 

Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via Freepost, HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.

Side effects should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com

Healthcare professionals and patients should also report Product Quality Complaints to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com

Product name Active Ingredient Strength and Pharmaceutical form

Adcortyl

Triamcinolone Acetonide

Intra-articular / Intradermal Injection 10 mg/ml

Amikin

Amikacin Sulfate

Injection 100 mg/2ml

Azactam

Aztreonam

1g and 2g Powder for Solution for Injection or Infusion

Baraclude

Entecavir monohydrate

0.05 mg/ml oral solution

Baraclude

Entecavir monohydrate

0.5 mg and 1.0 mg film-coated tablets

Capoten

Captopril

25 mg Tablets

Capoten

Captopril

50 mg Tablets

Capozide

Captopril/Hydrochlorothiazide

Captopril 50 mg / Hydrochlorothiazide 25 mg Tablets

Daklinza ▼ 

Daclatasvir dihydrochloride

30 mg, 60 mg film-coated tablets

Eliquis

Apixaban

2.5 mg tablet

Eliquis

Apixaban

5 mg tablet

Empliciti ▼ 

Elotuzumab

300 mg and 400 mg powder for concentrate for solution for infusion

Fungizone

Amphotericin B

50 mg Powder for Sterile Concentrate

Hydrea

Hydroxycarbamide

500 mg Hard Capsule

Lipostat

Pravastatin Sodium

10 mg Tablets

Lipostat

Pravastatin Sodium

20 mg Tablets

Lipostat

Pravastatin Sodium

40 mg Tablets

Modecate

Fluphenazine decanoate

Injection 25 mg / ml

Modecate

Fluphenazine decanoate

Concentrate 100 mg / ml Solution for injection

Mycostatin

Nystatin

Oral Suspension (ready mixed)

Nalorex

Naltrexone Hydrochloride

50 mg Film Coated Tablet

Nulojix

Belatacept

250 mg powder for concentrate for solution for infusion

Opdivo ▼ 

Nivolumab

10 mg/mL concentrate for solution for infusion

Orencia

Abatacept

250 mg Powder for concentrate for solution for infusion

Orencia

Abatacept

125 mg / ml Solution for Injection - pre-filled pen

Orencia

Abatacept

125 mg / ml Solution for Injection - pre-filled syringe

Perfalgan

Paracetamol

10 mg/ml Solution for Infusion

Questran

Colestyramine

4 g/sachet Powder for Oral Suspension

Reyataz

Atazanavir sulfate

150 mg hard capsule

Reyataz

Atazanavir sulfate

200 mg hard capsule

Reyataz

Atazanavir sulfate

300 mg hard capsule

Sotacor

Sotalol Hydrochloride

80 mg Tablet

Sprycel

Dasatinib

20 mg, 50 mg, 70 mg and 100 mg Film-Coated Tablets

Sustiva

Efavirenz

50 mg, 100 mg, 200 mg hard capsules

Sustiva

Efavirenz

600 mg film-coated tablets

Vepesid

Etoposide

50 mg and 100 mg Soft Capsule

Videx EC

Didanosine

125 mg, 200 mg, 250 mg & 400 mg Gastro-resistant Capsules

Yervoy

Ipilimumab

5 mg/ml solution for infusion

Zerit

Stavudine

30 mg and 40 mg Hard Capsules


Healthcare Professionals:

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via Freepost, HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie. Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com

Patients:

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via Freepost, HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine. Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com

Risk Minimisation

Risk Minimisation Materials (e.g. educational brochures, patient alert cards, posters etc) are intended to improve the use of a medicine by positively influencing health professionals and patients to reduce the risk and/or the severity of adverse reactions associated with a particular medicine.

These materials are additional to the medicine’s Summary of Product Characteristics and Patient Information Leaflet (http://www.medicines.ie) and their requirements are part of the product EU Risk Management Plan.

Only some medicines have a set of tailored risk minimisation materials developed for this purpose. These materials are reviewed and approved by the Health Products Regulatory Authority (HPRA). To access risk minimisation materials (where available electronically) for our medicines, please click on the link below to the HPRA website. Please note: after clicking link below you will then need to use the alphabet search function to access a medicine's risk minimisation materials. After searching by medicine, click on the educational materials section ("EdM").


After you click on the hyperlink below, you will be redirected to the HPRA website..

www.hpra.ie/homepage/medicines/medicines-information/find-a-medicine

If you would like a hard copy of a BMS medicine's risk minimisation materials posted out to you, please contact Bristol-Myers Squibb Medical Information (telephone: 1 800 749 749; e-mail: medical.information@bms.com) with your specific request.


Approval number: MLTIE1706439-04
Date: May 2018